Breast Carcinoma with Oncotype DX Recurrence Score Lower Than 18: Rate of Distant Metastases in a Large Series with Clinical Follow-Up

BACKGROUNDS: A 21-gene expression assay (Oncotype DX™ Recurrence Score (“RS”)) that utilizes RT-PCR is used clinically in early-stage estrogen receptor-positive, HER2-negative breast carcinoma (ER+/HER2− BC) to determine both prognosis with tamoxifen therapy and the utility of adding adjuvant chemot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Wen, Hannah Y, Krystel-Whittemore, Melissa, Patil, Sujata, Pareja, Fresia, Bowser, Zenica L, Dickler, Maura N., Norton, Larry, Morrow, Monica, Hudis, Clifford A., Brogi, Edi
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161549/
https://ncbi.nlm.nih.gov/pubmed/27526056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30271
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares